Genmab chief: Morale is sky high
Jan van de Winkel, CEO in Danish antibody company, Genmab, is thrilled with the latest Breakthrough Therapy designation for one of the company’s drugs. It will have a huge effect on how doctors assess the drug, he says.
by Benjamin Werner Christensen
Within less than five months Genmab has won the coveted Breakthrough Therapy designation from the FDA twice. And CEO Jan van de Winkel is clearly thrilled with the development, as Medwatch catches him on the phone immediately following the announcement of the latest Breakthrough designation.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
What are Genmab's actual plans for drug hope?
For abonnenter
.jpg&w=384&q=75){kind=logo}
